TrevogrumabCheck methods and identity
What an older sarcopenia trial measured with a body scan
3 numbered sourcesSource years 2013–2026
Peptides are short chains of amino acids connected by peptide bonds. They can act as signals or bind other molecules. Trevogrumab, also called REGN1033 in earlier studies, is a larger investigational antibody that blocks myostatin. An older randomized study in people with sarcopenia tested whether the antibody changed lean body mass over 12 weeks. [1, 2, 3]
The study compared three groups receiving the investigational antibody with a placebo group. The primary outcome in the European trial results was percentage change in total lean body mass measured by dual-energy X-ray absorptiometry, or DXA. The estimated group averages increased by about 1.2% to 1.8% with the antibody and declined by about 0.5% with placebo. These values describe the trial’s primary scan measurement. The registry also gives the number of participants in each group who had the measurements needed for this analysis. [1]
The registry also lists secondary physical performance measures. For example, investigators assessed aspects of gait in a timed walking test. These measures address a different outcome from how much fat-free tissue a scan estimates. A scan can detect a difference in tissue composition while a walking test depends on multiple systems, including strength, balance and coordination. Reporting one result cannot substitute for examining the other. [1]
This study examined people with sarcopenia and tested the antibody against placebo over a short period. It did not study the antibody during semaglutide-associated weight change. Its older European results record is direct human evidence for the scan question in its study population. Comparisons in other settings, including adding trevogrumab to a weight-management medication, need their own trial designs and outcomes. [1, 2, 3]
Sources
Original works cited in this article. Links open the external record in a new tab.
- 2.Regeneron Pharmaceuticals, Inc. A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Safety and Efficacy of 3-month Subcutaneous REGN1033 Treatment in Patients With Sarcopenia. ClinicalTrials.gov (publication 2013-10-16, record updated 2016-03-28). (opens in a new tab)
clinicaltrials.gov↩ Back to text
- 3.Regeneron Pharmaceuticals, Inc. A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity. ClinicalTrials.gov (publication 2024-03-07, record updated 2026-09-01). (opens in a new tab)
clinicaltrials.gov↩ Back to text
